Cargando…
Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
BACKGROUND: Anti-PD-1 and PD-L1 antibodies (mAbs) are approved immunotherapy agents to treat metastatic non-small cell lung cancer (NSCLC) patients. Only a minority of patients responds to these treatments and biomarkers predicting response are currently lacking. METHODS: Immunoscore-Immune-Checkpoi...
Autores principales: | Ghiringhelli, François, Bibeau, Frederic, Greillier, Laurent, Fumet, Jean-David, Ilie, Alis, Monville, Florence, Laugé, Caroline, Catteau, Aurélie, Boquet, Isabelle, Majdi, Amine, Morgand, Erwan, Oulkhouir, Youssef, Brandone, Nicolas, Adam, Julien, Sbarrato, Thomas, Kassambara, Alboukadel, Fieschi, Jacques, Garcia, Stéphane, Lepage, Anne Laure, Tomasini, Pascale, Galon, Jérôme |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232659/ https://www.ncbi.nlm.nih.gov/pubmed/37244159 http://dx.doi.org/10.1016/j.ebiom.2023.104633 |
Ejemplares similares
-
Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1
por: Galland, Loïck, et al.
Publicado: (2021) -
Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital Pathology) and Pathologist Visual Scoring
por: Boquet, Isabelle, et al.
Publicado: (2022) -
Clinicopathological and Prognostic Significance of Immunoscore and PD-L1 in Intrahepatic Cholangiocarcinoma
por: Wu, Hong, et al.
Publicado: (2021) -
Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination
por: Grapin, Mathieu, et al.
Publicado: (2019) -
Understanding Inflammasomes and PD-1/PD-L1 Crosstalk to Improve Cancer Treatment Efficiency
por: Perrichet, Anaïs, et al.
Publicado: (2020)